Clinical Trials Browser

Neoplasms, Plasma Cell × dacetuzumab × Plasma cell × Clear all

NCT00664898 2022-12-12

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell